Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti‐angiogenesis activity in a preclinical cancer model
Open Access
- 2 December 2014
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 106 (2), 201-207
- https://doi.org/10.1111/cas.12581
Abstract
Almost all cancers show intrinsic and/or evasive resistance to vascular endothelial growth factor (VEGF) inhibitors by multiple mechanisms. Serum angiopoietin‐2 (Ang2) level has been proposed as a potential biomarker of VEGF inhibitor response in several cancers. From these clinical observations, the Ang2 and Tie2 (its receptor) axis has been focused on as a promising target. Here, we show a novel strategy to circumvent the resistance by combining multi‐tyrosine kinase inhibitors lenvatinib (VEGF receptor, fibroblast growth factor receptor, and RET inhibitor) and golvatinib (E7050; c‐Met, Tie2, and EphB4 inhibitor). Tie2 identifies a highly pro‐angiogenic macrophage subset, Tie2‐expressing macrophages (TEM). Angi‐Tie2 and EphB4‐EphrinB2 signaling plays critical roles in pericyte‐mediated vessel stabilization. In vitro analyses suggested that golvatinib combined with lenvatinib inhibited pericyte‐mediated vessel stabilization and TEM differentiation. In thyroid and endometrial cancer models, golvatinib and lenvatinib inhibited pericyte network development and TEM infiltration, resulting in severe perfusion disorder and massive apoptosis. Body weight loss was tolerable, and no macroscopic change was observed. These preclinical studies suggest that modulation of the tumor microenvironment by a strategic and well‐tolerated combination of multi‐targeting tyrosine kinase inhibitors may sensitize cancer to VEGF inhibitors.Keywords
This publication has 24 references indexed in Scilit:
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancerInternational Journal of Cancer, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesisBMC Cancer, 2010
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapyBritish Journal of Cancer, 2010
- Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic FunctionsCancer Research, 2010
- A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationshipsBlood, 2009
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 KinaseClinical Cancer Research, 2008
- Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Blood vessel maturation in a 3‐dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsivenessThe FASEB Journal, 2001